The Coeur d'Alene Arthritis Clinic
Craig Wiesenhutter's Abstract Publications
Wiesenhutter, C.W., Diverse Disease Activity Measures Demonstrate That the Routine Assessment of Patient Index Data with 3 Measures (Rapid-3) Assesses Only Non Inflammatory Components of Disease and Should Not Be Utilized in a Treat To Target Strategy in Rheumatoid Arthritis. . Arthritis Rheumatol. 2017; 69 (suppl 10). <
Wiesenhutter, C.W., The Use of Eular Remission and Response Criteria and Diverse Disease Activity Measures Demonstrate that the Treatment of Rheumatoid Arthritis with Staph Protein A leads to Sustained Clinical Responses . Annals of the Rheumatic Diseases 2017 <
Wiesenhutter, C.W., The Use of a Blinded Truncated Power Doppler Validates Efficacy Data Fra;m an Early Phase Open Label Drug Study Treating Rheumatoid Arthritis. Annals of the Rheumatic Diseases 2017;76:232 <
Wiesenhutter, C.W., Body Mass Index is Positively Correlated with Diverse Disease Activity Measures in Longstanding Rheumatoid Arthritis. Arhthritis Rheumatism 2016
Wiesenhutter, C.W., Changes in Diverse Disease Activity Measures Are Highly Correlated Following the Initiation of Most Treatment Modalities in the Management of Longstanding Rheumatoid Arthritis. Arhthritis Rheumatism 2016
Wiesenhutter, C.W., Treatment of Rheumatoid Arthritis Patients with Parenteral Staphylococcal Protein A (PRTX-100): An Open-Label Single-Site Extension Trial. Ann Rheum Dis 2016;75:1019 doi:10.1136/annrheumdis-2016-eular.2540
Wiesenhutter, C.W., Utilization of Multiple Disease Activity Measures in Rheumatoid Arthritis patients detected a unique Subtype of Rheumatoid Arthritis. Ann Rheum Dis 2015;74:245 doi:10.1136/annrheumdis-2015-eular.1857
Wiesenhutter, C.W., Implementation of Treating Patients to Target in a Long Standing Rheumatoid Patient Population. Ann Rheum Dis 2015;74:445-446 doi:10.1136/annrheumdis-2015-eular.1856
Wiesenhutter, C.W., Rakesh, P, Lavery, J., Nighat, T., Hazan, Lydie, Kivitz, A., and B. Bretton. A Phase 1 Dose-Ranging Repeated-Dose Trial of Parenteral Staphylococcal Protein A (PRTX-100) in Patients with Active Rheumatoid Arthritis on Methotrexate or Leflunomide Therapy. Arhthritis Rheumatism 2014:
Wiesenhutter, C.W., Kivitz, A., Kaine, J., Lavery, J., Hazan, L. and E. Bernton. Phase I Study of Staphylococcal Protein A in Patients with Active Rheumatoid Arthritis on Methotrexate. Ann. Rheum. Dis. 2014: 73(Supp 2)
Cox, D.A., and C.W. Wiesenhutter. Immunoadsoption with Staph A Protein Columns (PROSORBA) Induces Marked Cryoglobulinemia in Patients Treated for Rheumatoid Arthritis. Arthritis Rheumatism 2002 (Supp) 46 (#9) P. S168 Abstract #362
Heidt Jr., Robert S. (Wellington Orthopaedic & Sports Medicine, Cincinnati, OH); Greenwald, Maria (Advanced in Medicine, Rancho Mirage, CA); Wiesenhutter, Craig W. (Coeur d’Alene Arthritis Clinic); Peters, Eric A. (Arizona Arthritis Clinic, Paradise Valley, AZ). Iontophoresis of Dexamethasone for Acute Humeral Epicondylitis: Controlled Trial of Safety and Efficacy. Presented at the meeting of the American Academy of Physical Medicine, September 2001.
Hemmings, F.J.; Banken, L.; Levy, R.; Wiesenhutter, C.; Sennewald, R.; Roche Products, Ltd., Welwyn Garden City, UK; f. Hoffman-LaRoche, Switzerland; Olympia Arthritis Clinic, Washington, USA; Coeur d’Alene Arthritis Clinic, Idaho, USA.; PHAROS GmbH, Ulm, Germany. The Use of Trocade with Oral Methotrexate and Oral Contraceptives. Presented at the Meeting of the European Congress of Rheumatology, June 2000
Abdulghani, A., Lipani, J., Yang, X-D, Lohner, M., Krueger, G., Gottlieb, A., Beutner, K., Levy, R., Wiesenhutter, C., Kang, X-D., and Camisa, C. A Multiple-Dose Clinical Trial of a Fully Human Anti-Interleuken 8 Antibody (ABX-IL8) for the Treatment of Psoriasis. Presented at Several Conferences, including the Clinical Dermatology Meeting in Vienna, May 2000.
Wiesenhutter, C., Levy, R., Luggen, M., Thomas, J., Tesser, J., Cooper, S., Susko, T., Tsuji, W, Kaine, J., Olejnik, T., Alkuzweny, B. and M. Totoritis. Results of a Placebo-Controlled, Dose-Escalating, Phase I/II Trial of Clenoliximab (IDEC-151), A Non-Depleting Primatized, Anti-CD4 Monoclonal Antibody in Patients with Rheumatoid Arthritis. Eular. “Podium Presenter” June 5, 1999, Glasgow, Scotland.
Krueger, G., Gottlieb, A., Levy, R., Wiesenhutter, C., Menter, A., Kang, S., Camisa, C., Lohner, M., Yang, X-D, Davis, C.G., and J. Lipani. A Single-Dose Clinical Trial of a Fully Human Anti-IL8 Antibody for the Treatment of Psoriasis. Hawaii Derm 1999 Meeting, Maui, Hawaii, Feb 12, 1999.
Tesser, J.R., Wiesenhutter, C.W., Levy, R., Schiff, M., Lipani, J., Solinger, A., MacDonald, B., Elliott, M., and K. Singh. Treatment of Rheumatoid Arthritis with a Primatized Anti-CD4 Monoclonal Antibody, SB-210396 (IDEC-CE9.1). Results of an Open-Label Extension Study in Patients Responding to Induction Therapy. Arthritis Rheumatism, 1997 Sept (Suppl.), 40 (#9): p. S224. Abstract #1160.
Hubbard, R.C., Koepp, R.J., Yu, S., Talwalker, S., Geis, G.S., Wiesenhutter, C.W., Makarowski, W.S. and H.A. Paulus. SC-58635 (CELECOXIB), A Novel Cox-2 Selective Inhibitor, Is Effective as a Treatment for Osteoarthritis (OA) in a Short-Term Pilot Study. Arthritis Rheumatism, 1996 Sept (Suppl.), 39 (#9): p. S123. Abstract #574.
Levy, R., Weisman, M., Wiesenhutter, C.W., Yocum, D., Schnitzer, T., Goldman, A., Schiff, M., Breedveld, F., Solinger, A., MacDonald, B. and J. Lipani. Results of a Placebo-Controlled, Multicenter Trial Using a Primatized Non-Depleting, Anti-CD4 Monoclonal Antibody in the Treatment of Rheumatoid Arthritis. Arthritis Rheumatism, 1996 Sept (Suppl.), 39 (#9): p. S123. Abstract #574. “Podium Presenter”.
Quagliata, F., Caldwell, J., Wiesenhutter, C.W., Bertram, J., Spindler, J., Balint, J., Yoshida, L. and F. Jones. Treatment of Rheumatoid Arthritis by Removal of Circulating Immune Complexes Using Extracorporeal Immunoadsorption. C. Exper. Rheumatology 1995 Sept (Suppl.), 13 (#S-12): p. S48. Abstract #33.
Kaine, J., Solinger, A., Yocum, D., Lipani, J., Klas, P., Tesser, J., Wiesenhutter, C.W., O’Sullivan, F., Shuman, S. and W. Rigby. Results of a Multi-Dose Protocol 7002 Using an Immunomodulating, Nondepleting Primatized Anti-CD4 Monoclonal Antibody in Rheumatoid Arthritis. Arthritis Rheumatism, 1995 Sept (Suppl.), 38 (#9): p. S185. Abstract #195.
Caldwell, J., Wiesenhutter, C.W., Bertram, J., Spindler, J. and F. Quagliata. Treatment of Rheumatoid Arthritis by Removal of Circulating Immune Complexes using Protein A Immunoadsorption of Plasma. Arthritis Rheumatism, 1995 Sept (Suppl.), 38 (#9): p. S282. Abstract #774.
Wiesenhutter, C.W. Treatment of Highly Refractory Rheumatoid Arthritis and Rheumatoid Vasculitis with Extracorporeal Immunoadsorption with Staph A Protein Columns: A Case Study. Arthritis Rheumatism, 1994 June (Suppl.), 37 (#6): p. R5. Abstract #4P. Western Region. Accepted for Plenary Session. “Podium Presenter”.
Wiesenhutter, C.W. and J.H. Bertram. Treatment of Refractory Rheumatoid Arthritis with Extracorporeal Protein A Immunoadsorption Columns: One Year Follow-Up. Arthritis Rheumatism, 1993 Sept (Suppl.), 36 (#9): p. S216. Abstract #C169
Wiesenhutter, C.W., Irish, B.L., and J.H. Bertram. The Treatment of Refractory Rheumatoid Arthritis by Extracorporeal Immunoadsorption with Staph A Protein Columns: A Pilot Trial. Arthritis Rheumatism, 1992 Sept (Suppl.), 35 (#9): p. S44. Abstract #60. Accepted for Plenary Session. “Podium Presenter”.
Wiesenhutter, C.W., Brenner, M.B., Kobayashi, S., Huberman, A., and D.T.Y. Yu. Participation of MHC Class I Proteins in the Interaction of Human Lymphocytes with a Reiter’s-Disease-Causing Bacteria. Arthritis Rheumatism (Suppl.), 1982 Apr; 25: p. 38. Abstract #215. Accepted for Plenary Session. “Podium Presenter”.
Brenner, M.B., Wiesenhutter, C.W., Huberman, A., Kobayashi, S. and D.T.Y Yu. A Specific T Lymphocyte Response in HLA-B27+ Reiter’s Disease. Arthritis Rheumatism (Suppl.), 1982 Apr; 25: p. 62. Abstract #354.